drugset
drugset / Trial / NCT04986436

Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of HS-10360 in Healthy Subjects.

NCT04986436 ↗

Phase 1 Unknown 76 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of single and multiple oral administered doses of HS-10360 in healthy subjects.

Timeline

Start
2021-07
Primary completion
2022-06
Completion
2022-06

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10360 Unknown — Oral

Indications

No indication recorded.